
    
      This study is an open-label, multicentered, single-arm and phase IV clinical trial. 300
      HIV-infected patients who received simplified treatment regimen (50mg DTG+ 400mg 3TC, oral,
      qd) were selected to observe the treatment efficacy. At week 24, 36, 48 and 96, the rate of
      viral suppression and CD4 cell count were calculated against baseline. In addition, the
      safety and drug compliance were also monitored.
    
  